Supernus Pharmaceuticals Price to Free Cash Flow Ratio 2011-2023 | SUPN
Historical price to free cash flow ratio values for Supernus Pharmaceuticals (SUPN) since 2011.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Supernus Pharmaceuticals Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-04-26 |
30.07 |
|
15.10 |
| 2023-12-31 |
28.94 |
$1.99 |
14.53 |
| 2023-09-30 |
27.57 |
$1.47 |
18.71 |
| 2023-06-30 |
30.06 |
$1.21 |
24.83 |
| 2023-03-31 |
36.23 |
$2.61 |
13.86 |
| 2022-12-31 |
35.67 |
$1.89 |
18.90 |
| 2022-09-30 |
33.85 |
$2.51 |
13.49 |
| 2022-06-30 |
28.92 |
$2.05 |
14.08 |
| 2022-03-31 |
32.32 |
$1.73 |
18.73 |
| 2021-12-31 |
29.16 |
$2.30 |
12.67 |
| 2021-09-30 |
26.67 |
$2.00 |
13.36 |
| 2021-06-30 |
30.79 |
$2.16 |
14.27 |
| 2021-03-31 |
26.18 |
$3.02 |
8.66 |
| 2020-12-31 |
25.16 |
$2.51 |
10.03 |
| 2020-09-30 |
20.84 |
$2.72 |
7.67 |
| 2020-06-30 |
23.75 |
$3.32 |
7.16 |
| 2020-03-31 |
17.99 |
$2.15 |
8.38 |
| 2019-12-31 |
23.72 |
$2.63 |
9.01 |
| 2019-09-30 |
27.48 |
$2.44 |
11.25 |
| 2019-06-30 |
33.09 |
$2.90 |
11.42 |
| 2019-03-31 |
35.04 |
$2.48 |
14.15 |
| 2018-12-31 |
33.22 |
$2.37 |
14.02 |
| 2018-09-30 |
50.35 |
$2.43 |
20.68 |
| 2018-06-30 |
59.85 |
$2.00 |
29.90 |
| 2018-03-31 |
45.80 |
$2.36 |
19.37 |
| 2017-12-31 |
39.85 |
$2.11 |
18.86 |
| 2017-09-30 |
40.00 |
$1.92 |
20.87 |
| 2017-06-30 |
43.10 |
$1.74 |
24.81 |
| 2017-03-31 |
31.30 |
$1.58 |
19.87 |
| 2016-12-31 |
25.25 |
$1.26 |
20.02 |
| 2016-09-30 |
24.73 |
$1.16 |
21.40 |
| 2016-06-30 |
20.37 |
$0.65 |
31.27 |
| 2016-03-31 |
15.25 |
$0.58 |
26.43 |
| 2015-12-31 |
13.44 |
$0.63 |
21.21 |
| 2015-09-30 |
14.03 |
$0.39 |
35.67 |
| 2015-06-30 |
16.98 |
$0.26 |
65.74 |
| 2015-03-31 |
12.09 |
$-0.13 |
0.00 |
| 2014-12-31 |
8.30 |
$-0.59 |
0.00 |
| 2014-09-30 |
8.69 |
$-0.99 |
0.00 |
| 2014-06-30 |
10.95 |
$-1.39 |
0.00 |
| 2014-03-31 |
8.94 |
$-1.77 |
0.00 |
| 2013-12-31 |
7.54 |
$-1.87 |
0.00 |
| 2013-09-30 |
7.33 |
$-3.07 |
0.00 |
| 2013-06-30 |
6.43 |
$-2.67 |
0.00 |
| 2013-03-31 |
5.62 |
$-3.32 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.604B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
